{"id":2766,"date":"2017-08-12T11:12:57","date_gmt":"2017-08-12T11:12:57","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/2017\/08\/12\/quasi-feasibility-studie-case-control-der-forbinder-dyb-lokal-hypertermibehandling-med-standard-kraeftbehandlinger-og-beskriver-responsmoenstre-esho\/"},"modified":"2025-09-02T09:18:43","modified_gmt":"2025-09-02T09:18:43","slug":"klinisk-forsog-hypertermi","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/da\/klinisk-forsog-hypertermi\/","title":{"rendered":"Kvasi-gennemf\u00f8rligheds klinisk fors\u00f8g, der forbinder behandling af dyb lokal hypertermi med standard kr\u00e6ftbehandlinger og beskriver responsm\u00f8nstre"},"content":{"rendered":"<h1 style=\"text-align: center;\"><a href=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/cartleESHOfinal.pdf\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kvasi-gennemf\u00f8rligheds klinisk fors\u00f8g, der forbinder behandling af dyb lokal hypertermi med standard kr\u00e6ftbehandlinger og beskriver responsm\u00f8nstre<\/span><\/span><\/a><\/h1>\n<h2 style=\"text-align: center;\"><a href=\"https:\/\/www.esho.info\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Klinisk fors\u00f8g med Andromedic hypertermi &#8211; Kongressen af \u200b\u200bdet europ\u00e6iske selskab for hypertermisk onkologi 2014\u00a0<\/span><\/span><\/a><\/h2>\n<figure id=\"attachment_111\" aria-describedby=\"caption-attachment-111\" style=\"width: 568px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-111 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg\" alt=\"Klinisk fors\u00f8g med hypertermi i Andromedic: Kvasi-forunders\u00f8gelse (case-kontrol), der forbinder dyb lokal hypertermibehandling med HyDeep 600WM med standard kr\u00e6ftbehandlinger og beskriver responsm\u00f8nstre\" width=\"568\" height=\"826\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg 568w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-206x300.jpg 206w\" sizes=\"auto, (max-width: 568px) 100vw, 568px\" \/><figcaption id=\"caption-attachment-111\" class=\"wp-caption-text\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kvasi-forunders\u00f8gelse (case-control) der forbinder dyb lokal hypertermi HyDeep 600WM-behandling med standard kr\u00e6ftbehandlinger og beskriver responsm\u00f8nstre<\/span><\/span><\/figcaption><\/figure>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Indledning:<\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dette er det f\u00f8rste kliniske fors\u00f8g, der kombinerer dyb lokal hypertermi med standard kr\u00e6ftbehandlinger i Spanien og Andalusien.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Materialer og metoder:<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u00e5l:<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">For det f\u00f8rste:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> At analysere de kliniske fordele, behandlingsrespons, behandlingsmulighed og komfort med hypertermi kombineret med standard kr\u00e6ftbehandlinger inden for det offentlige sundhedssystem. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sekund\u00e6rt:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> At analysere overlevelse, livskvalitet og toksicitet (generel og specifik kr\u00e6fthypertermi).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Design:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Et prospektivt, kvasi-eksperimentelt case-control-studie, hvor hypertermibehandlinger (6-10 sessioner, med en frekvens p\u00e5 2-3 om ugen) blev administreret i forbindelse med standard str\u00e5lebehandling (RT), kemoterapi (CT) eller en kombination af begge. Patienter med prim\u00e6re tumorer p\u00e5 9 steder eller metastatiske tumorer, behandlet med radikal eller kombineret behandling, blev retrospektivt sammenlignet med to kontroltilf\u00e6lde behandlet inden for det foreg\u00e5ende \u00e5r.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">To faser:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> f\u00f8rste l\u00e6ringsfase (20 patienter). Anden aktiv behandlingsfase med 97 patienter inkluderet, sammenlignet med 196 kontrolpersoner behandlet med str\u00e5lebehandling eller QT-intervalbehandling uden hypertermi i 2012 p\u00e5 begge hospitaler (i alt 293 patienter).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ni tumorsteder:<\/span><\/span><\/strong><\/p>\n<blockquote>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Livmoderhals, prostata, bl\u00e6re<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Bugspytkirtel, inoperabelt hoved og hals<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hjernetumorer, pr\u00e6operativ endetarm<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Inoperabel neoadjuverende behandling af fremskreden brystkr\u00e6ft<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ikke-sm\u00e5cellet lungekr\u00e6ft (NSCLC)<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palliativ behandling p\u00e5 forskellige steder<\/span><\/span><\/li>\n<\/ul>\n<\/blockquote>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Resultater:<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Forel\u00f8bige data fra listen:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 22 patienter (9 p\u00e5 Juan Roman Jimenez Hospital og 13 p\u00e5 Carlos Haya Hospital).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">K\u00f8n: 13 m\u00e6nd og 9 kvinder.<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Gennemsnitsalder: 55 \u00e5r (34-76 \u00e5r).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tumorplacering: Glioblastom (2c), hoved og hals (7c), pr\u00e6operativ endetarm (3c), bryst (3c1), lunge (11c), prostata (4c), livmoderhals (lc), metastase i sakroiliacale knogler.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Behandling:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> HyDeep 600WM hypertermiapparat (Andromedic) der administrerer 10 sessioner, 2-3 gange om ugen, af 1 times varighed, med et effektniveau p\u00e5 mellem 150 W og 400 W afh\u00e6ngigt af placeringen i forbindelse med standard onkologisk behandling.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00c5rsager til seponering af behandling:<\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Juan R Jim\u00e9nez Hospital i Huelva: 3 tilf\u00e6lde, infektion i stedet for behandling (cellulitis i endetarmskr\u00e6ft), livmoderbl\u00f8dning (livmoderhalskr\u00e6ft) og frivillig seponering.<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hospital C Haya de Melaga: 2 patienter, 1 i den 6. session, der havde tolereret det godt, og en anden i den 6. session p\u00e5 grund af veltolereret fremgang.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Patientresultat:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 19 er i live og afventer responsevaluering, og 3 patienter er d\u00f8de p\u00e5 grund af sygdomsprogression (2 modtager udelukkende kemoterapi og hormonbehandling p\u00e5 grund af tumortilbagefald i det tidligere bestr\u00e5lede hoved- og halsomr\u00e5de, og en anden patient med faryngeal tumortilbagefald modtager palliativ radioterapi og hormonbehandling).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tolerance: 81,2 % af patienterne (18 %) angav, at de var tilfredse eller meget tilfredse, og 18,8 % (4 %) angav, at de var acceptable.<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Toksicitet: Grad 1 br\u00e6ndende toksicitet forekom hos 8 ud af 22 patienter (36,3%). Ingen toksicitet forekom hos 66,6%. Smerter\/pr\u00e6mix i behandlingsomr\u00e5det, grad 1 (i ulcereret bryst), hos \u00e9n patient.<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vores forel\u00f8bige erfaringer tyder p\u00e5, at behandling kan udf\u00f8res p\u00e5 et offentligt hospital, i rutinem\u00e6ssig pleje uden behov for ekstraordin\u00e6re ressourcer og med h\u00f8j tolerance.<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">KONKLUSIONER: Behandlingen er gennemf\u00f8rlig og behagelig for 81,2% af vores patienter i det offentlige sundhedssystem, med mild toksicitet hos 33%, der kan tilskrives hypertermibehandling. Passende patientudv\u00e6lgelse er afg\u00f8rende.<\/span><\/span><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kvasi-gennemf\u00f8rligheds klinisk fors\u00f8g, der forbinder behandling af dyb lokal hypertermi med standard kr\u00e6ftbehandlinger og beskriver responsm\u00f8nstre Klinisk fors\u00f8g med Andromedic hypertermi &#8211; Kongressen af \u200b\u200bdet europ\u00e6iske selskab for hypertermisk onkologi 2014\u00a0 Indledning: Dette er det f\u00f8rste kliniske fors\u00f8g, der kombinerer dyb lokal hypertermi med standard kr\u00e6ftbehandlinger i Spanien og Andalusien. Materialer og metoder: M\u00e5l: For&hellip;<\/p>\n","protected":false},"author":1,"featured_media":1936,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[110,887],"tags":[],"class_list":["post-2766","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nyheder","category-studii-clinice-da"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/posts\/2766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/comments?post=2766"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/posts\/2766\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/media\/1936"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/media?parent=2766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/categories?post=2766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/tags?post=2766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}